🔴 Corcept Therapeutics is trading 5.5% down today as Nasdaq and S&P 500 slide

Corcept Therapeutics is trading at $109.86, down 5.5%, with broad market weakness the likeliest explanation; a specific cause for the larger decline is unconfirmed.

• The broader market is sharply lower, with the Nasdaq down 2.19% and the S&P 500 down 1.41%.
• No company-specific announcement explaining the decline was found in available coverage. The ADA/EASD screening recommendation citing Corcept’s CATALYST trial was supportive, not an apparent explanation for today’s drop.